05:04 PM EST, 01/08/2025 (MT Newswires) -- Zymeworks ( ZYME ) said Wednesday it exited 2024 with around $324 million in cash that should support its operations at projected levels into H2 2027, when combined with anticipated milestone payments.

The $324 million cash, cash equivalent reserve on Dec. 31 does not include a $25 milestone payment due in the current quarter from Jazz Pharmaceuticals (JAZZ) that was triggered by approval in the US of Ziihera bispecific antibody treatment for HER2-positive biliary tract cancer.

Zymeworks ( ZYME ) also said the company is well-positioned for additional progress with its drug pipeline to potential treat various autoimmune and inflammatory diseases as well as hematological cancers.